Ποια είναι η τιμή για Duopharma Biotech Berhad (7148)

Η τιμή για Duopharma Biotech Berhad (7148) είναι $0.32757535

Ποια είναι η κεφαλαιοποίηση αγοράς για Duopharma Biotech Berhad (7148)

Η κεφαλαιοποίηση αγοράς για Duopharma Biotech Berhad (7148) είναι $315.11M

Duopharma Biotech Berhad (7148) Τιμή και Κεφαλαιοποίηση Αγοράς

Duopharma Biotech Berhad, an investment holding firm, is actively engaged in the pharmaceutical sector. Its operations encompass the research, development, manufacturing, distribution, and import of medicinal products, serving markets in Malaysia and internationally. The company's extensive product range includes consumer health items like vitamins, nutritional supplements, pain relievers, eye care solutions, antacids, and skincare products. It also provides generic medications across various therapeutic classes, such as cardiovascular, dermatological, hormonal, respiratory, neurological, musculoskeletal, and anti-infective agents. Furthermore, Duopharma offers specialized pharmaceutical drugs for targeted conditions, biosimilar products, and medical devices and consumables, addressing ailments like diabetes, cancer, cardiovascular diseases, and renal disorders. Notable products include vascor, insugen, kytron, and unihepa. Its well-known brands feature Champs, Flavettes, Eye Glo, Proviton, Naturalle, and Uphamol. Beyond its core pharmaceutical activities, the company is also involved in property management and the trading of chemical products. Founded in 1978 and headquartered in Kuala Lumpur, Malaysia, the company adopted its current name, Duopharma Biotech Berhad, in February 2019, having previously been known as CCM Duopharma Biotech Berhad.

Η τιμή για 7148	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$5,454.71 $315.11M	NVDA	$5.247T	+1,665,076.96%
$4,959.65 $315.11M	AAPL	$4.771T	+1,513,947.34%
$4,186.61 $315.11M	GOOG	$4.027T	+1,277,960.77%
$3,871.03 $315.11M	MSFT	$3.724T	+1,181,623.29%
$2,847.00 $315.11M	AMZN	$2.739T	+869,013.00%

Η τιμή για 7148

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$5,454.71 $315.11M